METTL2A and adrenal cortex carcinoma: Respectively, METTL2A high expression was related to poor prognosis in Adrenocortical carcinoma, Breast invasive carcinoma (BRCA), KICH, Pancreatic adenocarcinoma (PAAD) and Uveal Melanoma (UVM), while low expression was related to poor prognosis in Esophageal carcinoma and Rectum adenocarcinoma (READ).